Wilkins Investment Counsel’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$17.2M Sell
112,677
-3,735
-3% -$573K 2.47% 13
2025
Q4
$16M Sell
116,412
-17,565
-13% -$2.3M 2.34% 15
2025
Q3
$17.2M Sell
133,977
-5,443
-4% -$664K 2.43% 14
2025
Q2
$16.9M Sell
139,420
-9,895
-7% -$1.12M 2.39% 16
2025
Q1
$16.6M Sell
149,315
-17,467
-10% -$1.86M 2.38% 13
2024
Q4
$16.2M Sell
166,782
-21,274
-11% -$2.27M 2.35% 14
2024
Q3
$21.6M Sell
188,056
-913
-0.5% -$104K 2.99% 7
2024
Q2
$20.1M Buy
188,969
+1,232
+0.7% +$124K 3% 6
2024
Q1
$18.2M Buy
187,737
+57,627
+44% +$5.91M 2.65% 11
2023
Q4
$13.1M Sell
130,110
-840
-0.6% -$81.1K 3.2% 8
2023
Q3
$13.3M Sell
130,950
-1,800
-1% -$183K 3.61% 5
2023
Q2
$13.4M Sell
132,750
-1,960
-1% -$196K 3.5% 5
2023
Q1
$12.4M Sell
134,710
-250
-0.2% -$21.8K 3.26% 7
2022
Q4
$12.2M Buy
134,960
+1,175
+0.9% +$99K 3.22% 9
2022
Q3
$10.2M Buy
133,785
+838
+0.6% +$69.5K 2.98% 8
2022
Q2
$11.2M Sell
132,947
-933
-0.7% -$81.9K 2.98% 9
2022
Q1
$11.7M Buy
133,880
+1,090
+0.8% +$94.4K 2.65% 13
2021
Q4
$11.6M Buy
132,790
+2,200
+2% +$183K 2.56% 15
2021
Q3
$10.7M Buy
130,590
+2,400
+2% +$216K 2.61% 14
2021
Q2
$11.7M Buy
128,190
+2,075
+2% +$185K 2.88% 12
2021
Q1
$10.8M Sell
126,115
-720
-0.6% -$64.6K 2.79% 14
2020
Q4
$12M Buy
126,835
+365
+0.3% +$31.9K 3.32% 6
2020
Q3
$11M Buy
126,470
+2,625
+2% +$227K 3.28% 7
2020
Q2
$10.8M Buy
123,845
+2,225
+2% +$192K 3.42% 5
2020
Q1
$10M Sell
121,620
-925
-0.8% -$82.5K 3.66% 6
2019
Q4
$11.6M Buy
122,545
+525
+0.4% +$47.1K 3.29% 8
2019
Q3
$10.6M Sell
122,020
-275
-0.2% -$24.7K 3.19% 8
2019
Q2
$11.2M Sell
122,295
-14,382
-11% -$1.22M 3.35% 7
2019
Q1
$11.8M Sell
136,677
-1,227
-0.9% -$98.5K 3.56% 6
2018
Q4
$10.6M Sell
137,904
-56
-0% -$4.36K 3.51% 6
2018
Q3
$10.7M Sell
137,960
-167
-0.1% -$12.3K 3.19% 12
2018
Q2
$9.35M Buy
138,127
+6,193
+5% +$427K 2.94% 12
2018
Q1
$9.56M Buy
131,934
+2,244
+2% +$171K 3.02% 11
2017
Q4
$9.76M Sell
129,690
-1,652
-1% -$125K 2.91% 12
2017
Q3
$10.1M Buy
131,342
+112
+0.1% +$8.46K 3.07% 11
2017
Q2
$9.81M Buy
131,230
+558
+0.4% +$39.5K 3.12% 11
2017
Q1
$8.7M Buy
130,672
+10,992
+9% +$732K 2.79% 13
2016
Q4
$7.81M Buy
119,680
+14,397
+14% +$934K 2.49% 18
2016
Q3
$7.45M Buy
105,283
+212
+0.2% +$15.4K 2.5% 17
2016
Q2
$7.77M Buy
105,071
+4,185
+4% +$289K 2.63% 16
2016
Q1
$6.55M Buy
100,886
+16,981
+20% +$1.16M 2.4% 18
2015
Q4
$6.47M Sell
83,905
-698
-0.8% -$55.4K 2.43% 17
2015
Q3
$6.97M Sell
84,603
-129
-0.2% -$11.5K 2.67% 15
2015
Q2
$7.47M Sell
84,732
-1,367
-2% -$125K 2.72% 13
2015
Q1
$7.61M Sell
86,099
-391
-0.5% -$34.7K 2.69% 13
2014
Q4
$7.18M Sell
86,490
-558
-0.6% -$46.3K 2.5% 15
2014
Q3
$7.34M Sell
87,048
-614
-0.7% -$49.7K 2.62% 15
2014
Q2
$7.11M Buy
87,662
+223
+0.3% +$17.5K 2.51% 17
2014
Q1
$6.66M Sell
87,439
-446
-0.5% -$32.5K 2.46% 17
2013
Q4
$6.33M Buy
87,885
+84
+0.1% +$5.84K 2.63% 17
2013
Q3
$6.04M Sell
87,801
-1,674
-2% -$111K 2.75% 16
2013
Q2
$5.67M Buy
+89,475
New +$5.82M 2.63% 17

Other funds holding NVS

Wilkins Investment Counsel's NVS Position: Q1 2026 in Review

Wilkins Investment Counsel reduced its Novartis (NVS) stake by 3.2% in Q1 2026, selling an estimated $573K and leaving 112,677 shares worth $17.2M. The position accounts for 2.47% of the portfolio, ranked #13.

Wilkins Investment Counsel first reported a position in NVS in Q2 2013 and has held it in 52 quarters since. The position peaked at $21.6M in Q3 2024. 1,592 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Wilkins Investment Counsel held 112,677 shares of Novartis worth $17.2M as of Q1 2026.
  • Wilkins Investment Counsel sold 3,735 Novartis shares in Q1 2026, an estimated $573K.
  • Novartis made up 2.47% of Wilkins Investment Counsel's portfolio in Q1 2026, its #13 holding.
  • Wilkins Investment Counsel first reported a position in Novartis in Q2 2013 and has held it in 52 quarters since.
  • Wilkins Investment Counsel's Novartis position peaked at $21.6M in Q3 2024.
  • 1,592 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Wilkins Investment Counsel's 13F filing for Q1 2026, filed 7 May 2026.